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ABSTRACT 
Candida auris has emerged as a significant global nosocomial pathogen. This is 
primarily due to its antifungal resistance profile, but also its capacity to form adherent 
biofilm communities on a range of clinically important substrates. While we have a 
comprehensive understanding how other Candida species resist and respond to 
antifungal challenge within the sessile phenotype, our current understanding of C. auris 
biofilm mediated resistance is lacking. In this study we are the first to perform 
transcriptomic analysis of temporally developing C. auris biofilms, which were shown 
to exhibit phase and antifungal class dependent resistance profiles. A de novo 
transcriptome assembly was performed, where sequenced sample reads were assembled 
into a ~11.5 Mb transcriptome consisting of 5848 genes. Differential expression (DE) 
analysis demonstrated that 791 and 464 genes were up-regulated in biofilm formation 
and planktonic cells respectively, with a minimum 2-fold change. Adhesin related GPI-
anchored cell wall genes were up-regulated at all time-points of biofilm formation. As 
the biofilm developed into intermediate and mature stages, a number of genes encoding 
efflux pumps were up-regulated, including ATP-binding cassette (ABC) and major 
facilitator superfamily (MFS) transporters. When we assessed efflux pump activity 
biochemically, biofilms efflux was greater than planktonic cells at 12 and 24 h. When 
these were inhibited, fluconazole sensitivity was enhanced 4 to 16-fold. This study 
demonstrates the importance of efflux mediated resistance within complex C. auris 
communities and may explain its resilience to a range of antimicrobial agents within 
the hospital environment. 
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IMPORTANCE  
Fungal infections represent an important cause of human morbidity and mortality, 
particularly if they adhere and grow on both biological and inanimate surfaces as 
communities of cells (biofilms). Recently, a previously unrecognized yeast Candida 
auris has emerged globally that has led to widespread concern due to our difficulty in 
treating it with existing antifungal agents. Alarmingly, it is also able to grow as a 
biofilm that is highly resistant to antifungal agents, yet we are unclear how it does this. 
Here we used a molecular approach to investigate the genes that are important in 
causing the cells to be resistant within the biofilm. The work provides significant 
insights into the importance of efflux pumps, which actively pump out toxic antifungal 
drugs, and therefore enhance their survival within a variety of harsh environments.  
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INTRODUCTION 
Fungal infections affect in excess of a billion people, resulting in approximately 11.5 
million life-threatening infections and more than 1.5 million deaths annually (1). 
Candida auris is an emerging fungal pathogen that has attracted considerable attention 
because of its ability to cause infections that are both difficult to diagnose and to treat 
(2). It has been responsible for a number of nosocomial outbreaks worldwide through 
its ability to persistently colonise and transmit between patients and the environment 
(3-6). Despite the unprecedented global emergence of this organism, relatively little is 
known about the molecular basis of its pathogenicity and antifungal resistance 
phenotype. The resistance profile is well documented, with >90% of isolates 
intrinsically resistant to fluconazole. Resistance to other azoles, polyenes and 
echinocandins has also been reported (4). Alarmingly, 41% of isolates have been shown 
to be multidrug resistant, with 4% demonstrating pan-drug resistance (4). Hot-spot 
mutations in ERG11 and FKS1 have been identified as resistance mechanisms in azole 
and echinocandin resistant strains respectively (7, 8).  
 
Candida biofilms represent an important clinical entity associated with adaptive 
resistance to many antifungals, and are linked to excess morbidity and mortality (9-11). 
Although, C. albicans is regarded as the primary biofilm-forming pathogen within the 
genus, there is increasing interest and evidence for non-Candida albicans species 
biofilms (12, 13), particularly in C. auris. Clinically, C. auris has been isolated from a 
number of sites including wounds, line-tips and catheters, suggestive of the organism 
existing within a biofilm-lifestyle in host (14, 15).  We recently described the ability of 
C. auris to form anti-fungal resistant biofilms, against all 3 main classes of antifungals 
(16), yet the mechanisms underlying this phenotype remain unknown. The speed of 
 5 
discovery in this emerging pathogen has certainly been hindered by the lack of robust 
sequence information. Initial sequencing efforts provided a draft C. auris genome, 
however, these reads were poorly aligned to other Candida spp. and inconsistently 
annotated (17). More recently, complete and functionally annotated genome assemblies 
have been created, allowing the analysis of the functional capacity of the genome to be 
studied under clinically relevant conditions (18). Biofilm-associated resistance is a 
complex and multifaceted phenomenon that has been described in number of fungal 
pathogens. Various resistance mechanisms exist, predominately associated with the 
extracellular matrix (ECM), overexpression of drug targets and efflux pumps (19). 
Given the lack of understanding of biofilm formation and resistance mechanisms in C. 
auris, we therefore aimed to investigate these mechanisms using a transcriptomics 
approach.  
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MATERIALS AND METHODS 
 
Microbial growth and standardisation 
Four C. auris clinical isolates were used throughout this study (NCPF8971, NCPF8973, 
NCPF8984, NCPF8990) (20). Isolates were stored in Microbank vials at -80°C prior to 
use, before they were sub-cultured onto Sabouraud dextrose agar (SAB [Sigma, Dorset, 
UK]) and incubated at 30°C for 48 h. Isolates were propagated overnight in yeast 
peptone dextrose (YPD) media (Sigma, Dorset, UK), before washing with 
centrifugation as previously described (21). Cells were then standardised to 1 x 106 
cells/mL in RPMI-1640 media and biofilms were grown in micro-titre plates, 75cm2 
tissue culture flasks, or Thermanox™ coverslips) for 4, 12 and 24 h at 37°C. 
 
Characterisation of biofilm formation. 
Isolates were standardised as described above and grown for 4, 12 and 24 h at 37°C. 
Following growth, biofilms were washed with phosphate buffered saline (PBS [Sigma, 
Dorset, UK]) and biomass quantified using the crystal violet assay, as previously 
described (21). In addition, biofilm composition was analysed using a propidium 
monoazide (PMA) qPCR, a method able to differentiate live cells from a population 
(22). Samples were prepared as previously described (22), before sonication in 1mL of 
PBS at 35kHz for 10 min in an ultrasonic water bath to remove and disaggregate the 
biofilm (23). After sonication, samples were incubated in the dark with 50 μM PMA 
(Cambridge Bioscience, Cambridge, UK) for 10 min to allow uptake of the dye. All 
samples were then exposed for 5 min to a 650W halogen light before DNA was 
extracted using the QIAamp DNA mini kit, as per manufacturer's protocol (Qiagen, 
Crawley, UK). One microliter of extracted DNA was then added to a mastermix 
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containing Fast SYBR® Green Master Mix, RNase free water and 10μM of C auris 
specific forward and reverse primers (Forward – CGCACATTGCGCCTTGGGGTA; 
Reverse - GTAGTCCTACCTGATTTGAGGC GAC) (24). Real-time qPCR was then 
used to enumerate the total of number of live cells from within the biofilm, using the 
following thermal profile: 50°C for 2 min, 95°C for 2 min, followed by 40 cycles of 
95°C for 3 sec and 60°C for 30 sec. Colony forming equivalents (CFE) were then 
calculated based upon a standard curve of serially extracted DNA ranging from 1 x 108 
- 1 x 104 cells/mL. 
 
Biofilm visualisation 
Biofilms were standardised and grown on Thermanox™ coverslips (Fisher Scientific, 
Loughborough, UK) as described above. At selected time points, biofilms were washed 
with PBS before processing for scanning electron microscopy (SEM). Biofilms were 
fixed in 2% para-formaldehyde, 2% glutaraldehyde, 0.15M sodium cacodylate, and 
0.15% w/v alcian blue, before processing as previously described (21). Biofilms were 
then sputter coated in gold before being viewed under a JOEL-JSM-6400 microscope.  
 
Planktonic and sessile susceptibility testing 
Planktonic minimum inhibitory concentrations (pMIC) were determined visually using 
the Clinical Laboratory Standards Institute M27-A3 broth microdilution method (25). 
Standardised cells were treated with serial two-fold dilutions of miconazole nitrate 
(0.25-128mg/L), micafungin (0.25-128mg/L) and amphotericin B (0.063-32mg/L). In 
addition, biofilms were grown for 4, 12 and 24 hr as described above before treatment 
with the same concentrations as planktonic cells. Sessile MICs (sMIC) were determined 
using the XTT metabolic reduction assay (26). The sMIC was calculated as the 
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concentration leading to 80% reduction in XTT-colorimetric readings in comparison to 
an untreated positive control. 
 
RNA extraction and sequencing analysis 
Following biofilm characterisation, C. auris NCPF 8973, originally isolated from a 
wound swab (14) was chosen for subsequent transcriptomic analysis. Biofilms were 
grown as described above in 75cm3 tissue culture flasks, before being washed with PBS 
and biomass was dislodged using a cell-scraper. The resultant biofilm biomass was then 
homogenised using a bead-beater and RNA extracted using the TrizolTM (Life 
Technologies, Paisley, UK) method (27). Following extraction, RNA was DNase 
treated and purified using the RNeasy MiniElute clean up kit as per the manufacturer’s 
instructions. Quality and quantity were assessed using a bioanalyser (Agilent, USA), 
where a minimum quantity of 2.5μg and a minimum quality RIN value of 7.0 was 
obtained for each sample. Samples were then submitted to Edinburgh Genomics 
(http://genomics.ed.ac.uk/) before sequencing using the HiSeq 2500 Illumina 
sequencer. Biological triplicates were analysed for all variables, with the exception of 
4 h biofilms to which two replicates were used due to sequencing failure. 
 
Transcriptome annotation and differential expression analysis 
Raw fastq reads were quality controlled using Trim Galore v0.4.5 
(https://github.com/FelixKrueger/TrimGalore) to remove Illumina adapters and trim 
reads with a quality score lower than 20. Reads were then aligned to the refseq genome 
sequence B8441 using HISAT2 (28). The aligned reads were then coordinate sorted 
and SAM files were converted to BAM before all aligned reads were merged using 
samtools (29). The resulting aligned reads were assembled de novo using genome 
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guided Trinity v2.5.1 (28). The completed transcriptome was assessed by using the 
contig length distribution metrics (N50), percentage of annotation and the third-party 
Benchmarking Universal Single-Copy Orthologs (BUSCO) v3 assessment program 
(http://busco.ezlab.org/). Annotation of candidate open reading frames (ORFS), 
identified with TransDecoder v5.0.2 (http://transdecoder.sourceforge.net/), was then 
performed using the Trinotate v3.1.0 package (https://trinotate.github.io/). Trinotate 
performs functional annotation of transcriptomes from the uniprot Swiss-Prot database 
via homology searches with the Basic Local Alignment Search Tool (BLAST) 
functions BLASTp for protein queries and BLASTx for nucleotide queries. Gene 
Ontology (GO) and Kyoto Encyclopaedia of Genes and Genomes (KEGG), EggNOG 
identifiers were also inferred from the Swiss-Prot protein database. BLAST2GO 
annotation was additionally performed which also relies upon BLAST but includes the 
annotation from European Bioinformatics Institute (EBI) InterPro databases. The 
extraction through to the annotation is summarised in Figure 2. The reference 
transcriptome created by Trinity was used to create an index the trimmed reads were 
then counted and annotated against this index using gene abundance quantification 
software Kallisto. Gene abundance files for each sample replicate were than imported 
into R for differential analysis based upon the DESeq2 package. All additional 
statistics, analysis and visualisation were produced within R. Raw data files are 
deposited at the following site: https://www.ncbi.nlm.nih.gov/bioproject/423159. 
 
Temporal efflux pump activity and inhibition  
The efflux pump activity of planktonic and sessile cells was assessed using the alanine 
-naphthylamine (Ala-nap) fluorescent assay was used as previously described (29). 
For planktonic assessment, four C auris isolates were standardised to 5 x 107 cells/mL 
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in the assay buffer solution (MgSO2 [1mM], K2HPO4 [50mM], and 0.4% glucose; pH 
7.0). For sessile cells, biofilms were grown in black flat-bottomed microtitre plates for 
12 and 24 h. Following biofilm development, these were washed with the assay buffer 
solution. The reaction was then initiated with the addition of 100μg/mL Ala-nap and 
developed for 60 min at 37°C. Fluorescence readings were obtained every 30sec using 
a fluorescence plate reader at an emission/excitation wavelength of 355/460nm. In 
addition, the efflux pump inhibitor ([EPI] L-Phe-L-Arg--naphthylamine 
dihydrochloride) was used in combination with fluconazole to determine if antifungal 
activity could be enhanced. Biofilms were developed in the presence of fluconazole 
(128-0.25 mg/L) with and without the presence of EPI at a concentration of 64 mg/L 
and incubated for 12 and 24 h at 37°C. Biofilms were then washed with PBS, before 
viability was calculated using the XTT assay as described above.  
 
Statistical analysis 
Graph production, data distribution and statistical analysis were created using 
GraphPad Prism (version 8; La Jolla, CA, USA) and R studio (version 1.1). For efflux 
pump activity experiments, data was normalised before student t test were used to 
compare samples. Statistical significance was achieved if p<0.05. 
 
Data availability 
 
Raw HiSeq sequencing reads (50bp) and assembly are available under sequence read 
archive submission: SUB3362956. Average of all gene expression values are available 
in supplementary datasheet 2. Gene and functional annotations are submitted in 
datasheet 1 and figures S1-3. 
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RESULTS 
Candida auris biofilms exhibit temporal antifungal resistance 
Mature Candida auris biofilms have been shown to be resistant to antifungals that are 
readily active against their planktonic equivalents (16). We therefore investigated the 
temporal effect of biofilm formation against the susceptibility to of all three major 
classes of antifungals. As demonstrated in Fig 1A, the maturation of C. auris biofilms 
was shown to correlate with decreased susceptibility to each antifungal agent. When 
assessed planktonically, the median MIC for the four isolates for miconazole was 
1g/mL, micafungin <0.25g/mL and amphotericin B 0.5g/mL (range 0.125-
0.5g/mL). After 4 h of biofilm development, no increases in resistance were observed 
against micafungin (MIC <0.25g/mL), however the median MIC increased 16-fold to 
16g/mL (range 16-32g/mL) for miconazole and 4-fold to 2g/mL for amphotericin 
B (range 1-4g/mL). As the biofilm matured to 12 h of growth, 2-fold increase in 
median MIC were shown for miconazole (range 16-64g/mL) and amphotericin B 
(range 2-4g/mL). Interestingly, the MIC was shown to significantly increase for 
micafungin (range 1->128g/mL) after 12 h. After 24 h, no further increase in MIC was 
observed for amphotericin B. However, both miconazole and micafungin MICs were 
increased 2-fold to 64g/mL and >128g/mL, respectively.  
 
Candida auris transcriptome assembly  
Given the temporal patterns of biofilm-associated resistance, we undertook a 
transcriptional profiling approach to understand the mechanisms governing antifungal 
biofilm resistance. Sequencing of samples using Illumina HiSeq produced around 414 
million single end reads of 50 bp length. Following processing, the number of reads 
were reduced by three million through trimming and quality control stages. All 
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sequenced sample reads were then assembled into a ~11.5 Mb transcriptome which 
consisted of 5889 identified Trinity transcripts and 5848 genes based on the longest 
isoform of transcripts. At least half of the assembled sequenced bases were found on 
contigs of a length of 3488 bp (N50) (Table 1). The completeness and quality of the C. 
auris transcriptome was assessed with BUSCO against Ascomycota (94%), 
Saccharomyceta (91.4%) and Saccharomycetales (91.7%) gene sets. Very small 
percentages of duplicate, fragmented and missing genes were observed in each of the 
gene sets (Table 2).  
 
Identification by sequence homology searches with BLASTx function yielded 
annotation of 54% of Trinity transcripts and 54% of unique ‘genes’. Identification of 
protein sequences with BLASTp, against Transdecoder identified ORFs and potential 
coding sequences, gave functional annotation matches with 51% of the transcripts and 
41% of unique ‘genes’ (Table 1). The presence of known signal peptides, functional 
protein domains and protein topology was discerned by searches against the SignalP 
and TmHMM databases, respectively. Of the predicted proteins, 202 sequences were 
predicted to have signal peptides and 701 transmembrane protein topologies were 
predicted. 
 
Additional annotation via the software BLAST2GO was performed, which obtains 
BLAST hits that are used to retrieve, and map GO and KEGG terms. It also utilises 
InterProScan which acquires functional annotation of protein sequences from EBI’s 
InterPro databases (https://www.ebi.ac.uk/interpro/). These databases are consortium 
of online databases that include PANTHER, Pfam and SUPERFAMILY (30). Both the 
Trinotate and BLAST2GO annotation files are supplied as supplementary datasheet 1.   
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BLAST2GO searches were performed with a fungi taxonomical filter, which annotated 
1157 genes with BLAST and an additional 4365 from the InterPro databases. InterPro 
and BLAST derived GO terms were merged to give a total of 9504 GO annotations 
assigned to 2,479 genes. These annotations were distributed between three main GO 
categories; Biological Process (3,633, 38%), Cellular Component (3116, 33%) and 
Molecular Function (2755, 29%) having the least (fig S1).  InterProScan was able to 
classify Trinity transcripts according to SuperFamilys based on known structures. The 
most represented superfamilies were the P-loop containing nucleoside triphosphate 
hydrolase (236) the major facilitator superfamily (113), Armadillo-type fold (102) and 
Protein Kinase-like superfamily (90) (fig S2). From annotation against the available 
databases, there were 6 major enzyme classes represented that included: Hydrolyases 
(290), Transferases (150), oxidoreductases (88), ligases (42), lyases (28) and 
isomerases (15) (fig S3).  
 
Differential expression and functional annotation of C. auris biofilms 
Differential expression (DE) analysis was performed to investigate the transcriptional 
changes observed with biofilm development. Multivariate analysis by principal 
component analysis (PCA) demonstrates variance between the different time points, 0 
h shows the greatest variance with the other biofilm time points. In addition, there is 
also some variance between biofilms at 4, 12 and 24h (Figure 3A). DE analysis 
demonstrated that 791 and 464 genes were up-regulated in biofilm formation and 
planktonic cells respectively, with a minimum 2-fold change (Figure 3A). Phase-
dependent differential expression of these up-regulated genes are illustrated in the venn 
diagram in Figure 3B, with the down-regulated genes shown in Figure 3C, individual 
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genes are described in supplementary datasheet 2. Of these biofilm up-regulated genes, 
selected genes involved in antifungal resistance and biofilm-associated mechanisms are 
listed in Table 3. GPI-anchored cell wall genes including IFF4, CSA1, PGA26 and 
PGA52 were up-regulated at all time-points of biofilm formation, highlighting their 
potential role within cellular adhesion (Table 3). Two further adhesins, HYR3 and ALS5 
were also shown to be up-regulated, but only in mature biofilms (Table 3). As the 
biofilm developed into intermediate and mature stages, a number of genes encoding 
efflux pumps were up-regulated including RDC3, SNQ2, CDR1, YHD3. In addition, 
MDR1 was shown to be up-regulated at the 24 h time point (Table 3). To understand 
the functional processes related to differentially expressed genes, a cut-off of 2-fold up-
regulation (adjusted p value <0.05) was used for gene ontology (G0) analysis 
comparing planktonic cells to 24 h biofilms. The 278 differentially expressed genes 
were assigned to 28 GO terms with an over enrichment P value <0.05, comprising 13 
biological processes, 9 cellular components and 6 molecular function, and contained a 
number of differentially expressed functional categories (Figure 4A). Included within 
these GO terms were transmembrane transport, within which several ATP-binding 
cassette (ABC) and major facilitator superfamily (MFS) transporters were highly up-
regulated in C. auris biofilms (Figure 4B). 
 
Efflux pumps play a primary role in antifungal resistance in C. auris biofilms 
Transcriptional analysis and function annotation revealed a significant up-regulation of 
a number of drug efflux pumps, from both ABC and MFS transporters. To confirm the 
role of these membrane proteins within biofilms, we assessed efflux pump activity. 
Both 12 and 24 h biofilms exhibited increased efflux compared to planktonic cells, with 
4 h biofilms below the detectable limit of the assay. Efflux from 12 h biofilms was 2.21-
 15 
fold (p<0.05) greater than planktonic cells, with a 2.38-fold increase shown in 24 h 
biofilms (p<0.005). No statistical differences were observed between 12 and 24 h 
biofilms (Figure 5). Interestingly, efflux pump activity is shown to be constitutively 
expressed within biofilms, with no induction observed in response to azole antifungals 
(Fig S4). 
 
Given the increased activity of efflux pumps in biofilms, we then assessed the 
contribution of these transporters to fluconazole sensitivity (Table 4). When biofilms 
were incubated for 12 h in the presence of fluconazole, the SMIC50 ranged between 32-
>128g/mL. However, when also grown in the presence of fluconazole and an EPI, the 
SMIC50 ranged between 2-16g/mL for all isolates, ranging from a 4 to 16-fold increase 
in susceptibility. The same trend was observed for 24 h biofilms, with the SMIC50 range 
between 64->128g/mL for fluconazole only treatment, with 2-8-fold reductions 
observed with co-incubation with the EPI (SMIC50 8-64g/mL). 
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Discussion 
The rapid and simultaneous emergence of the pathogenic yeast C. auris, combined with 
its reported recalcitrance to all three major classes of antifungals, has led to a concerted 
response by the medical mycology community to understand and define the 
mechanisms underpinning its pathogenicity and resistance. Although preliminary 
investigations have investigated genetic point mutations promoting resistance (7, 8), as 
well as number of efflux pumps identified within its genome (17, 18), there are still 
substantial gaps remaining in our understanding. Moreover, irrespective of these 
defined chromosomally derived resistance characteristics, adaptive resistance 
mechanisms associated with environmental stressors is likely to be a key contributor to 
its success as a pathogen both in the host and environment. We have recently reported 
how C. auris exhibit enhanced pathogenicity and resistance, both in vitro and in vivo, 
and that the biofilm phenotype is instrumental in its lifestyle (14, 16, 31, 32). Moreover, 
its ability to survive and persist in the nosocomial environment, increasing the 
probability to cause outbreaks. We have recently reported that adherent C. auris cells 
display substrate dependent susceptibility to clinically relevant concentrations of 
hospital disinfectants (32), and that these biofilms were shown to be resistant to 
chlorhexidine and hydrogen peroxide, displaying a less susceptible phenotype than C. 
albicans and C. glabrata (31). Here we report for the first time that efflux-based 
resistance mechanisms play an important role in biofilm mediated resistance in C. auris, 
and that conserved biofilm-related genes are temporally observed, as illustrated in 
Figure 6.    
   
To investigate this, we undertook an RNA-sequencing based approach for the analysis 
C. auris biofilm development, as well as profiling genes associated with resistance and 
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virulence mechanisms. Assembly of the transcriptome using trinity software has 
allowed us to construct a specific reference for our samples of interest. Additionally, 
annotation via numerous methods has allowed for a in depth functional characterisation 
of the organism. Annotation of homologs, predicted protein domains, as well as gene 
ontological classifications further enhances our ability to interpret mechanisms that 
differentiate C. auris under different conditions. This annotated transcriptome has been 
highly instrumental in expression analysis and elucidation of virulence mechanisms of 
C. auris in this and forthcoming studies. 
 
The initiation of biofilm formation depends on an initial adherence phase of 
colonisation to a specific surface before subsequent proliferation to promote disease. A 
number of GPI-linked cell wall proteins were up-regulated at the early biofilm time-
point, highlighting their role in the initial adherence stage. In C. albicans, IFF4 and 
CSA1 have been shown to be involved in adherence to both mucosal and abiotic 
substrates, as well as cell-cell cohesion (33-35). Transcriptional studies from Fox and 
coworkers (2015) identified IFF4 as a member of a group 10 adhesion genes that are 
induced at the later stages of biofilm formation, and hypothesise its role mediating cell-
cell contact (36). Interestingly, an iff4Δ null mutant displayed decreased adhesion at an 
early stage of biofilm formation, as well as attenuated virulence (37). Both studies 
collectively highlight its function throughout biofilm formation.  
 
In C. albicans, members of the agglutinin-like sequence (ALS) proteins play a key role 
in the adherence of the organism, predominantly through ALS3 (38, 39).  A recent study 
identified that members of this cell wall protein family detected in C. albicans are not 
found in C. auris (18). Our analysis revealed that orthologs of only two members, ALS1 
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and ALS5, were represented within the C. auris transcriptome, with the latter up-
regulated within mature biofilms. Further examination of cell wall protein families by 
Muñoz and coworkers (2018) failed to reveal any highly expanded families (18). It is 
therefore likely that a less reliant Als-dependent adherence mechanism exists for C. 
auris. Moreover, the gene encoding candidapepsin-5, commonly known as SAP5 in C. 
albicans was shown to be up-regulated in mature biofilms. This protease is 
predominantly associated with its role in invasive infection (40). Indeed, studies have 
identified its increased expression in biofilm associated infections (41), with sap5Δ/Δ 
strains demonstrating a less adherent phenotype, therefore highlighting its potential as 
a promising biofilm biomarker (42).  
 
One of the most defining characteristic of biofilms is their recalcitrance to antimicrobial 
agents. As described in other Candida spp. biofilm associated drug resistance 
comprises a number of different mechanisms that co-ordinate with one another through 
the various phases of biofilm development (43). An underlying mechanism across 
Candida spp. is the up-regulation of efflux pumps within biofilm associated cells (44-
46). Planktonically, C. auris isolates displayed up to 15 times fold more ABC-
transporter activity than C. glabrata isolates (15), highlighting a potential intrinsic 
azole resistance mechanism. Ramage and co-workers (2002) demonstrated that 
expression of CDR1 and MDR1 was increased within mature C. albicans biofilms 
compared to their planktonically grown equivalents, yet deletion of these genes had no 
effect on the susceptibility of mature biofilms (47). Indeed, temporal efflux pump 
analysis revealed that efflux pump mutants were more susceptible to fluconazole 
treatment than their parental strain at early phases of biofilm development (46), as also 
shown in other fungal pathogens, such as Aspergillus fumigatus (29). Our own temporal 
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analysis of C. auris biofilms revealed that efflux pumps were up-regulated at 
intermediate and mature phases of development unlike other species, though did not 
appear to be inducible following azole exposure. This is in contrast to analysis of C. 
glabrata biofilms exposed to azole treatment, where up-regulation of genes encoding 
ABC-transporters was observed (45). Muñoz et al (2018) recently analysed the 
transcriptional profile of planktonic C. auris in response to azole and polyene 
antifungals (18). After exposure of a resistant C. auris strain to amphotericin B almost 
40 genes were shown to be differentially expressed. These included genes involved in 
iron transport that have previously been described in C. albicans to be involved in its 
response to amphotericin B (48). Three genes of these genes (SIT1, PGA7, RBT5) were 
shown to overlap within our own biofilm data set indicating that these may play an 
additional role in our observed polyene resistance.  
 
A further key mechanism of Candida biofilm resistance is the formation of the ECM, 
which functions to provide stability and sequestration of drugs from the biofilm, as well 
as protection from environmental stressors (49). Recent studies have now identified that 
varying Candida spp. conserve a constitutive polysaccharide backbone that functions 
to impede antifungal delivery, yet the composition of the ECM varies between species 
(50, 51). Although its composition remains unknown, it could be hypothesised that C. 
auris ECM would be similar to that of C. glabrata, given the yeast cell biofilm 
phenotype. Temporal analysis has shown the formation of the ECM is time-dependent 
and associated with intermediate and maturation phases of biofilm formation (52). Our 
data suggests that this is similar in C. auris, with increased expression of KRE6 and 
EXG, a glucan 1,3-beta-glucosidase and a close ortholog of XOG1 in C. albicans, two 
genes involved in matrix formation (53, 54). 
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Given the alarming global emergence of antifungal resistance, then the requirement for 
new antifungals is pivotal (55). Drug efficacy and development has plateaued in recent 
years, yet an encouraging number of molecules remain within the antifungal pipeline 
(56, 57). Several studies have assessed the positive efficacy of novel compounds, 
including APX001, CD101, SCY078 and ceragenins against C. auris (58-61), which 
may widen the spectrum of active agents against emerging resistant species. These 
actives are both expansions of current drug targets, such as 1,3-β-glucan synthase 
inhibitors (CD101 and SCY078), as well as novel targets GPI-protein inhibitors 
(APX001). All of these compounds demonstrated significant in vitro activity against 
planktonic forms of C. auris, with APX001 also demonstrating enhanced in vivo 
efficacy compared to anidulafungin (60, 62). Although these preliminary data are very 
promising, there are limited studies evaluating their effect against sessile C. auris. The 
1,3-β-glucan synthase inhibitor SCY078 was shown to significantly reduce biofilm 
thickness and metabolic activity after a prolonged 48 h exposure (63). Furthermore, the 
ceragenins, a class of antimicrobial peptide, CSA-44 and CSA-131 also demonstrated 
anti-biofilm activity, although the concentrations needed were 4-64 fold greater than 
the planktonically active equivalent (61). APX001 is a first in class compound that acts 
by blocking GPI synthesis through inhibition of the GPI-anchored cell wall transfer 
protein 1 (Gwt1). Although no such studies have been performed, then perhaps 
APX001 is the most attractive anti-biofilm target, given our identified function of GPI-
anchored proteins in C. auris biofilm formation. 
 
Given that we can now genetically manipulate this pathogenic yeast (64, 65), future 
work analysing the functional roles and processes of specific genes and protein will 
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further enhance our understanding of biofilm-associated pathogenicity and resistance. 
Unravelling the key factors that regulate the transcriptional network that exists for C. 
auris, similar to those studies in C. albicans and C. parapsilosis (36, 66), may provide 
translational insights into novel avenues for therapeutic targets for biofilm-associated 
infections. We have shown that efflux pumps are important during biofilm 
development, and this may explain why this seemingly innocuous yeast is able to 
survive, persist and cause continued problems within the hospital setting. 
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Figure 1: Candida auris biofilm development correlates with increased antifungal 
tolerance 
Candida auris biofilms were standardised 1x106 CFU/mL and grown for 4, 12 and 24 
h. Biofilm biomass was then quantified using the crystal violet assay, with the 
composition of biofilm cells enumerated using qPCR and represented by a box and 
whisker plot as the total biomass of four C. auris isolates ([left hand y-axis], A). 
Planktonic susceptibility testing was performed against serially diluted miconazole, 
micafungin and amphotericin B concentrations using the CLSI guidelines, with biofilm 
susceptibility testing performed using the XTT assay, with median MIC values plotted 
([right hand y-axis], A). In addition, biofilms were grown, fixed and processed for SEM 
before imaging using a JEOL-JSM 6400 scanning electron microscope. Micrographs 
represent lower magnification (x1000) and higher magnification (inset, x5000) (B).  
 
Figure 2: Bioinformatic pipeline for Candida auris transcriptome assembly, 
annotation and analysis. 
 
Figure 3: Quality control and differential expression analysis of C. auris biofilms 
Principal component analysis displays the largest variance along PC1 (56%) and the 
second largest variance between samples PC2 (15%) (A). Venn diagrams of the genes 
upregulated (B) and downregulated (C) in biofilm time points (4, 12 and 24h) 
compared to 0h. 
 
Figure 4: Functional annotation of differentially expressed genes reveals up-
regulation of drug transporters 
Gene distribution of significantly upregulated C. auris genes in 24 h biofilms relative 
to planktonic cells, grouped into biological process (BP), cellular component (CC) and 
metabolic function (MF) gene ontology categories (A). Log2 fold change of up-
regulated ABC and MFS drug transporters within 24 h biofilms (B). All GO terms have 
a p.value of <0.05 based upon the GOSep hypergeometric distribution test.   
 
Figure 5: Efflux pump activity is increased in Candida auris biofilms 
Candida auris biofilms were grown for 4, 12 and 24 h in black-bottomed 96 well plates. 
In addition, planktonic cells were standardised to 5 x 107 cells/mL and all cells were 
incubated with 100μg/mL of Ala-Nap and fluorescence measurements were read at 30 
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sec intervals over 60 min (Ex355/Em460). Data represents the mean + SD of 4 isolates 
repeated on 3 independent occasions. Data presented is relative fluorescence units 
normalised per individual cell. *p<0.05, **p<0.01, ND – not detectable  
 
Figure 6: Formation and development of Candida auris biofilms 
Schematic representation of the transcriptional mediators of the three main stages of C. 
auris biofilm development: adherence to yeast cells to surface (early phase), 
proliferation (intermediate phase) and maturation into a structured biofilm (mature 
phase). 
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Table 1. Summarised statistics for the transcriptome assembly of Candida auris, 
the alignment rate of raw reads to the transcriptome and also a summary of the 
Trinotate functional annotation.  
All reads 414364539 
Reads after trimming 411626529 
  
Total assembled bases 11593681 
GC content % 45.35 
Total trinity "genes" 5848 
Total trinity "transcripts" 5889 
Contig N50 (bp) 3488 
Median contig (bp) 1308 
Average contig (bp) 1983 
  
 Reads aligned 
Reads aligned 1 time 393124946 (95.51%) 
Reads aligned > 1  9368727(2.28%) 
Overall 402493673 (97.78%) 
  
Functional annotation No. Transcripts 
Swissprot matches BLASTx 3200 
Swissprot unique Proteins BLASTx 3176 
Swissprot matches BLASTp 3041 
Swissprot unique proteins BLASTp 3019 
TmHMM 701 
SignalP 202 
Gene Ontology  3085 
KEGG 2889 
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Table 2. Assessment of Candida auris transcriptome assembly by benchmarking 
universal single-copy orthologs (BUSCO). 
 Ascomycota Saccharomyceta Saccharomycetales 
% complete 94 91.4 91.7 
% complete single copy 93.4 90.5 90.9 
% complete duplicated  0.6 0.9 0.8 
% fragmented 3.4 4.8 4.6 
% missing 2.6 3.8 3.7 
Total number of genes 1315 1759 1711 
 
Table 3. Up-regulated biofilm and resistance associated genes. 
 
  Fold change compared to planktonic (log2) 
Gene ID Function 4 hr 12 hr 24 hr 
IFF4 Adhesion 2.29 5.01 3.62 
PGA26 Adhesion 2.02 3.90 2.55 
PGA52 Adhesion 2.22 2.38 2.42 
CSA1 Adhesion 3.87 6.47 6.43 
PGA7 Adhesion - 3.94 4.82 
HYR3 Adhesion - - 2.06 
ALS5 Adhesion - - 3.82 
RDC3 Efflux pump - 4.29 3.91 
SNQ2 Efflux pump - 2.63 3.42 
CDR1 Efflux pump - 2.30 3.19 
YHD3 Efflux pump - 2.14 2.15 
MDR1 Efflux pump - - 2.3 
KRE6 Extracellular 
Matrix 
- 3.92 3.09 
EXG Extracellular 
Matrix 
- 2.69 2.26 
SAP5 Hydrolytic 
enzyme 
- - 2.19 
PLB3 Hydrolytic 
enzyme 
- - 2.13 
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Table 4. Inhibition of efflux pumps increases azole susceptibility 
 
Fluconazole (SMIC50) 
 12 h 24 h 
Isolate number + EPI* - EPI Fold 
change 
+ EPI - EPI Fold 
change 
NCPF 8971 16 64 4 16 >128 ≥8 
NCPF8973 2 32 16 8 64 8 
NCPF 8984 16 >128 ≥8 64 >128 ≥2 
NCPF 8990 8 32 4 16 64 4 
*EPI - efflux pump inhibitor 
 
 
 
 
 
 
 
 
 
 
